Genito Urinary System and Sex Hormones

Pharma News for Amgen BioNTech and Gilead

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial

Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The full data was presented as a late-breaker later at the ESMO 2022, so it is subject to change, but it currently shows a significant reduction in disease progression or death in patients with KRAS inhibitor in KRAS G12C-mutated NSCLC compared to docetaxel, but no improvement in overall survival. Amgen points out that the study was not statistically powered to...

Explore More...